批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2021/02/17 |
SUPPL-41(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/05/10 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/04/27 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/03/15 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/02/24 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/09/30 |
SUPPL-34(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/05/18 |
SUPPL-31(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/03/12 |
SUPPL-30(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/18 |
SUPPL-29(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2011/05/13 |
SUPPL-28(补充) |
Approval |
REMS |
N/A
|
|
|
2011/03/31 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/08/04 |
SUPPL-24(补充) |
Approval |
REMS |
N/A
|
|
|
2009/03/09 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/05/07 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/08/11 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/05/10 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2005/05/13 |
SUPPL-11(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2003/11/26 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2003/10/31 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2002/10/08 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/08/13 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/07/24 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2002/06/04 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/06/04 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/02/05 |
SUPPL-2(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2001/07/13 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2000/11/14 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE 剂型/给药途径:TABLET;ORAL 规格:EQ 300MG BASE;150MG;300MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021205 |
001 |
NDA |
TRIZIVIR |
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE |
TABLET;ORAL |
EQ 300MG BASE;150MG;300MG |
Discontinued |
Yes |
No |
AB |
2000/11/14
|
VIIV HLTHCARE |
202912 |
001 |
ANDA |
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE |
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE |
TABLET;ORAL |
EQ 300MG BASE;150MG;300MG |
Prescription |
No |
Yes |
AB |
2013/12/05
|
LUPIN LTD |